Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: Systematic review and meta‑analysis of clinical trials
Frontiers | Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi | Oncology
Adding Vorinostat to Revlimid Post-transplant Maintenance Therapy… – Myeloma Research News
Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma - Kang - 2021 - Journal of Cellular Physiology - Wiley Online Library
Summary of Phase I vorinostat trials | Download Table
The Mechanism of Action of the Histone Deacetylase Inhibitor Vorinostat Involves Interaction with the Insulin-Like Growth Factor Signaling Pathway
Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition | Cell Death & Disease
Clinical trials of vorinostat in combination therapy in patients with... | Download Table
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies | Scientific Reports
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug | Nature Biotechnology
Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data -
Vorinostat (SAHA) in clinical trials (N/A-not analyzed). | Download Scientific Diagram
References in Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial - The Lancet Oncology
Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat - Experimental Hematology
Delivery systems for vorinostat in cancer treatment: An updated review - ScienceDirect
Characteristics of HDAC inhibitors in clinical trials. | Download Table
Vorinostat - Wikipedia
Vorinostat in solid and hematologic malignancies | Journal of Hematology & Oncology | Full Text
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells - Okubo - 2020 - Cancer Science - Wiley Online Library
Targeting histone deacetylases: development of vorinostat for the treatment of cancer | Epigenomics
Vorinostat Eliminates Multicellular Resistance of Mesothelioma 3D Spheroids via Restoration of Noxa Expression
